Related Experiment Video

Updated: Jun 24, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Decoding CLU (Clusterin): Conquering cancer treatment resistance and immunological barriers

Maa Mamun1, Yi-Chao Zheng1, Ning Wang2

  • 1State Key Laboratory of Esophageal Cancer Prevention & Treatment Institute of Drug Discovery and Development, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450001, China.

International Immunopharmacology
|June 8, 2024
PubMed

Insights

Clusterin (CLU) protein promotes cancer treatment resistance by supporting tumor growth and immune evasion. Understanding CLU

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Cancer treatment resistance is a major obstacle, leading to disease progression and treatment failure.
  • Clusterin (CLU), a chaperone protein, is implicated in resistance to chemotherapy, radiation, and targeted therapies.
  • CLU also plays a role in creating an immunosuppressive tumor microenvironment (TME).

Purpose of the Study:

  • To investigate the mechanisms by which CLU promotes cancer treatment resistance.
  • To explore CLU's role in oncogenic signaling and cell death inhibition.
  • To identify strategies for overcoming CLU-mediated resistance to enhance cancer therapy effectiveness.

Main Methods:

  • Literature review and analysis of existing research on CLU in cancer.
  • Examination of CLU's impact on cancer cell signaling pathways.
  • Investigation of CLU's influence on the tumor microenvironment (TME) and immune response.

Main Results:

  • CLU confers resistance to multiple cancer treatment modalities.
  • CLU contributes to tumor cell survival by inhibiting apoptosis.
  • CLU actively modulates the TME to promote immune evasion and treatment resistance.

Conclusions:

  • CLU is a significant factor in cancer treatment failure.
  • Targeting CLU presents a promising strategy to overcome therapeutic resistance.
  • Further research into CLU mechanisms can lead to improved oncology treatment outcomes.
Keywords:
ClusterinImmunosuppressionTherapy resistance

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

323
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K